Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
暂无分享,去创建一个
Tae-Hwan Kim | S. Visvanathan | M. Østergaard | D. Baeten | J. Sieper | A. Solinger | C. Salvarani | L. Tam | S. Padula | Chandrasena R Pamulapati | D. Hall | P. Scholl | S. Aslanyan | Y. Datsenko | P. Järvinen | J. Wei